1

Evaluating risk detection methods to uncover ontogenic mediated adverse drug effect mechanisms in children

- 3 Authors:
- 4 Nicholas P. Giangreco^{1,2} and Nicholas P. Tatonetti^{1,*}
- ⁵ ¹Departments of Systems Biology and Biomedical Informatics, Columbia University, 622 W.
- 6 168th Street, New York, NY, 10032
- 7 ²npg2108@cumc.columbia.edu, ORCID: 0000-0001-8138-4947
- 8 *Correspondence: npt2105@cumc.columbia.edu, ORCID: 0000-0002-2700-2597

9 Abstract

10 **Background:** Identifying adverse drugs effects (ADEs) in children is essential for preventing disability and death from marketed drugs. At the same time, however, detection is challenging 11 12 due to dynamic biological processes during growth and maturation, called ontogeny, that alter pharmacokinetics and pharmacodynamics. As a result, current data mining methodologies have 13 14 been limited to event surveillance and have not focused on investigating adverse event 15 mechanisms. There is an opportunity to design data mining methodologies to identify and evaluate drug event patterns within observational databases for ontogenic-mediated adverse 16 17 event mechanisms. The first step of which is to establish statistical models that can identify 18 temporal trends of adverse effects across childhood. **Results:** Using simulation, we evaluated a 19 population stratification method (the proportional reporting ratio or PRR) and a population 20 modeling method (the generalized additive model or GAM) to identify and quantify ADE risk at 21 varying reporting rates and dynamics. We found that GAMs showed improved performance over 22 the PRR in detecting dynamic drug event reporting across child developmental stages. Moreover, 23 GAMs exhibited normally distributed and robust ADE risk estimation at all development stages 24 by sharing information across child development stages. Conclusions: Our study underscores the 25 opportunity for using population modeling techniques, which leverages drug event reporting across development stages, to identify adverse drug effect risk resulting from ontogenic 26 27 mechanisms.

28 Keywords

29 Pharmacovigilance, Pediatrics, Child Development, Modeling, Dynamics

2

30 Background

31	Adverse drug events (ADEs) in children are common and can result in injury and death ^{1,2} .
32	Clinical trials rarely include children ³ and pediatric-specific trials are limited in identifying
33	possible ADEs in the population ⁴ . Pediatric drug safety studies can evaluate large numbers of
34	ADEs from the population ⁵ but current methodologies are limited in their ability to identify the
35	mechanisms that drive pediatric ADEs ⁶ . Children undergo evolutionarily conserved and
36	physiologically dynamic biological processes, collectively called ontogeny, as they grow and
37	develop from birth through adolescence ^{7,8} . The mechanisms may include varying protein
38	activity ^{9,10} as well as include functional and structural changes that occur during maturation ^{11,12} .
39	These ontogenic changes can alter pharmacodynamics and pharmacokinetics resulting in adverse
40	effects, as is the case for doxorubicin-induced cardiotoxicity ¹³ and valproate-induced
41	hepatotoxicity ¹⁴ . With a few notable exceptions, however, many pediatric adverse events are
42	idiopathic with no known, clear connection to developmental biology ^{15,16} . Additionally, adverse
43	event mechanisms established in adults may not translate to the pediatric population ¹⁷ . There is
44	an opportunity to combine known ontogenic biology with real-world pediatric drug effect data to
45	identify ontogenic-mediated adverse events.

To date, elucidation of ontogenic mechanisms has relied on hypothesis-driven approaches. For example, juvenile mouse models have been used to identify genetic vulnerabilities of hematopoiesis¹⁸ and investigate effects by a glutamatergic agonist on the neural developmental sequence¹⁹ during early life. More recently, pharmacometric tools have been used to extrapolate drug effects from adults to children, such as projecting acetaminophen exposure across pediatric age groups²⁰, and investigate drug action in children, such as predicting clearance of zidovudine

3

during infancy²¹. However, juvenile animal studies are low-throughput and require complex 52 study designs²², and there is limited experimental data to parameterize manually designed 53 pharmacometric models^{23,24}. While lacking specificity, top-down studies are complementary in 54 55 that they evaluate thousands of hypotheses simultaneously and can identify idiosyncratic effects that would otherwise go unnoticed^{25,26}. Moreover, analyses of large population datasets start 56 from clinically significant events which can take decades to identify^{27,28}. Top-down studies can 57 close the pediatric evidence gap²³ by sifting through large databases to identify clinically 58 59 significant although perhaps less studied and rare adverse drug events during the period of child 60 growth and development. 61 While pediatric pharmacovigilance has been able to identify adverse drug events, it is limited in 62 identifying growth and development processes that underlie those observations^{10,29}. A common 63 approach when identifying ADEs is to stratify the pediatric population into age groups which 64 directly reduces the amount of data available to identify ADEs during childhood. The 65 Proportional Reporting Ratio, which was designed to be sensitive even when data is scarce³⁰, is 66 an established detection method and has been shown to unmask ADE signal within child 67 development stages compared to detection within the larger pediatric population³¹. However, 68 reduced data within these strata was shown to significantly affect PRR detection performance 69 across pediatric age groups³¹. To investigate pediatric ADEs, the continuous, time-dependent

biological processes during growth and development suggest using all information across childdevelopment stages.

Generalized additive models (GAMs) are supervised machine learning approaches that can
 quantify non-linear effects reflective of natural phenomena³². GAMs may be able to quantify
 signal reflecting dynamic, continuous processes such as ontogeny. These models are extensively

4

75 used for spatial and temporal analysis in ecological studies³³, such as explaining cardiovascular mortality risk from heat waves over time³⁴ and rat infestation from environmental factors within 76 geographic areas³⁵. Similar to evaluating ecological responses using shared information across 77 78 time or space, we can evaluate adverse events from temporally-connected ontogenic processes 79 using shared information across child development stages. 80 We performed the first study to directly evaluate dynamic drug event reporting during childhood. 81 We performed a data simulation and augmentation study that 1) simulated drug event reporting 82 temporal trends of different effect sizes and shapes, 2) augmented existing pediatric drug event 83 data by inserting the simulated reporting rates within observational data, and 3) evaluated 84 population stratification (PRR) and modeling (GAM) methods to detect these injected ADE 85 reporting dynamics. We found the detection scores generated by the GAM showed improved risk 86 estimates and increased detection of drug event reporting among the various simulated dynamics 87 compared to the PRR. Detection methods that capture temporal adverse drug event dynamics 88 within observational databases can improve our understanding of the interactions between child

I B

89 developmental biology and adverse drug effects.

90 **Results**

91 Pediatric FAERS

92 There were 339,741 pediatric drug event reports in FAERS, which contained 519,555 unique 93 drug-event pairs. We randomly sampled 500 drug-event pairs to be augmented with simulated 94 drug event reporting dynamics, representing our positive control set. We then randomly sampled 95 another 10,000 complementary drug-event pairs where the underlying data was untouched,

representing our negative control set. We showed there was no significant difference in the

96

97	amount of drug-event reporting between FAERS and the negative control (2-sample Student t-
98	test p-value=0.92) or positive control (p-value=0.87) drug-event pairs (Figure 1).
99	Data simulation and augmentation
100	We augmented the 500 drug-event pairs in the positive control set with simulated drug event
101	reporting across child development stages (see Methods). Augmenting the positive control data
102	with drug event reporting dynamics did not have a systematic effect on the amount of drug event
103	reporting compared to the untouched negative control set (Figure S1). However, applying the
104	PRR and GAM detection methods onto the positive control data showed the ADE risk scores
105	reflected the simulated dynamics classes (Figure 2).
106	
107	The GAM generated ADE risk that resembled normally distributed scores (Shapiro-Wilk test
108	average p-value and 95% confidence interval: 0.45 [0.059, 0.88], 90mse: 0.20 [4.67E-04, 0.92])
109	in comparison to the PRR (score: 0.11 [1.80E-09, 0.56], 90mse: 0.077 [2.48E-09, 0.93]) at child
110	development stages (Figure 3A). Moreover, 47% of PRR scores were zero and 18% were unable
111	to be computed, on average for drug-event pairs (Figure 3B).
112	ADE dynamics detection performance
113	We compared the performance of the GAM and PRR for detecting drug event reporting
114	dynamics (see Methods). Additionally, we further investigated the performance contribution by
115	each child development stage within the dynamics class. We found that the GAM had improved
116	detection of drug event reporting dynamics compared to the PRR both overall (Figure 4A) and
117	within each child development stage (Figure 4B). Moreover, the GAM had similar overall

6

performance (Figure 5) as well as sensitivity (Figure S3) at low drug event reporting comparedto the sensitive-by-design PRR.

- 120 *ADE dynamics sensitivity analysis*
- 121 We investigated the detection of drug event reporting dynamics with increasingly rare adverse
- 122 events within child development stages (Figure S4 and see Methods). The ADE risk scores
- 123 generated by the GAM showed dependent, flexible risk estimates across child development
- stages unlike the PRR (Figure S5). We found that the GAM had significantly higher performance
- 125 (Figure 6) and sensitivity (Figure S5) to detect the various drug event reporting dynamics as
- adverse events became rare at child development stages.

127 Real-world validation

128 We compared the performance of the GAM and PRR for detecting drug-event pairs in a real-

129 world pediatric reference set of 26 drug-event pairs (see Methods and Figure S6). We found that

the GAM had slightly improved overall performance and sensitivity compared to the PRR for

131 detecting pediatric adverse drug events (Table 1 and Figure S7). Moreover, we found no

132 difference in the fraction of drug-event pairs with significant ADE risk at child development

133 stages (Table 2; proportion test p-value=0.39). We found that the GAM identified two real-world

134 pediatric drug events with putative dynamic ADE risk (Figure 7). Specifically, the GAM showed

135 periods of lower risk during early and late childhood and higher risk during the middle stages of

136 childhood. While the PRR and GAM performed approximately the same overall, the GAM

137 captured dynamic ADE risk where the PRR did not.

7

138 Discussion

139	Children undergo a period of dynamic growth and development, presenting a challenge in
140	identifying and evaluating adverse drug events ^{10,36} . We hypothesize that dynamic ontogenic
141	processes as children grow and develop may be reflected by temporal drug event reporting in the
142	population. We presented the first study to evaluate drug event reporting patterns across
143	childhood in large observational data. We found that GAMs, a population modeling technique,
144	outperformed the PRR, a population stratification method, as well as generated robust risk scores
145	to detect adverse drug events during childhood. This work represents a first step in transitioning
146	from performing event surveillance towards uncovering putative mechanisms of pediatric
147	adverse drug events.

148 The goal of our study is to improve the specificity of top-down data mining for generating 149 pediatric drug safety hypotheses. Our study hypothesis was temporal drug event reporting trends 150 found in observational data are dependent on ontogeny, which exhibits high and low molecular 151 and physiological levels throughout childhood^{7,37,38}. To test this within a top-down approach, we 152 generated temporal trends in observational data to correspond with temporal trends from ontogeny as opposed to identifying temporal trends from frequency³⁹ or feature-derived^{40,41} 153 154 measures directly from observed data. This motivated both simulating dynamic drug event 155 reporting rates and then augmenting real-world data to generate different classes of dynamic 156 drug event reporting trends. While we simulated dynamic drug event reporting rates, we showed 157 that augmenting the FAERS data did not change the overall characteristics of the pediatric drug 158 reports. This was crucial for establishing the use of real-world drug event data to evaluate hidden 159 dynamic reporting trends. Importantly the ADE detection methods were in fact able to identify

8

the simulated dynamics within the data. The data simulation and augmentation of FAERS laid
the foundation for evaluating statistical methods to investigate ontogenic-mediated adverse event
mechanisms.

163 We found that the generalized additive model (GAM) showed improved detection of dynamic 164 drug event reporting compared to the proportional reporting ratio (PRR). While the PRR 165 produces ADE risk scores that were more erratic and unable to be computed, the GAM scores 166 were both more flexible and robust. The GAM assumes a flexible relationship yet reduces 167 'wiggliness' to stable risk estimates based on observed data^{42,43}. While bayesian modeling 168 techniques such as Monte Carlo Markov Chain can also learn flexible relationships from 169 observed data, these models still require expert knowledge to build, implement, and interpret⁴⁴. 170 The GAM, on the other hand, generates an interpretable smooth relationship in a familiar 171 regression framework³² that shares information across child development stages. Using this 172 shared information framework, the GAM was able to detect injected dynamic ADE risks across 173 childhood even when drug event reporting was low. We further showed that the GAM not only 174 generated visually dynamic ADE risk when injecting dynamics, but we also identified putative 175 dynamic risk for real-world psychiatric adverse events from exposure to montelukast medication 176 (Figure S8). We demonstrated that GAMs can be used to detect dynamic reporting of adverse 177 drug events by sharing information across child development stages.

This study has some limitations. First, observational data has inherent bias and confounding factors which may affect both the sample of drug-event pairs in our study as well as the performance of the detection methods. We showed that the random sample of drug events correspond to the reporting patterns found in the FAERS database. Also, performing a power analysis allowed for identifying drug events for which the detection methods were able to

9

183 identify the dynamic reporting to provide a fair performance comparison. Second, other 184 regulatory agencies, such as the Food and Drug Administration and European Medicines 185 Agency, define pediatric age ranges for development stages by different methods. While varying 186 child stage definitions were not explored here, we chose stages defined by NICHD that were 187 established after consultation and agreement among several US-based organizations such as the 188 American Academy of Pediatrics and the Centers for Disease Control and Prevention⁴⁵. Third, 189 fixed development stages may serve more useful in drug regulations and trial design than 190 representing dynamic child growth and development. Nevertheless, the detection performance 191 and risk scores for both methods could only be compared when considering data found within 192 child development strata. Fortunately, the further advantage of the GAM is its ability to model 193 childhood as a continuous period using age without restrictive strata. This increases the sharing 194 of information for identifying adverse event risk during childhood which may cross development 195 stages and affect specific periods during childhood.

196 **Conclusion**

197 In this study, we evaluated ADE risk detection methods to identify dynamic drug event reporting 198 within observational data. By simulating drug event reporting and augmenting simulated rates 199 into existing observational data, we can make comparisons between methods to detect dynamic 200 drug event reporting patterns. We found GAMs result in more robust scores, overall improved 201 performance to detect dynamics, and improved ability to detect simulated and real-world 202 pediatric drug-events compared to the state-of-the-art PRR method. This study lays the 203 foundation to detect and evaluate pediatric adverse drug events for ontogenic-mediated 204 mechanisms.



Fig. 1 Comparison of drug event reporting in drug-event datasets. A boxplot summary overlayed by the amount of drug event reports for drug-event pairs between (pediatric) FAERS (N=519,555), the positive control set (N=500), and the negative control set (N=10000). 'N' is the sample size.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.10.21253302; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.





Fig. 2 ADE detection method risk score distribution across child development stages. Risk scores resulting from applying the A) GAM and B) PRR ADE detection methods on the positive control drug-event pair data for each dynamics class. The score distributions at each child development stage were produced after 100 bootstraps of the original scores for each method and score type. We show the average difference of the resampled score distributions between a given drug event reporting dynamics class and uniform (random drug event reporting across childhood) with the 95% confidence interval.







Fig. 4 GAM and PRR drug event dynamic detection performance. A) The receiver operating characteristic curves showing the true positive rate versus the false positive rate for each method and score type by drug event reporting dynamics class. B) The area under the receiver operating characteristic curve (AUROC) for each child development stage within each dynamics class.



Fig. 5 GAM and PRR detection performance at low drug event reporting. The AUROC was computed for each method and score type to detect dynamics only utilizing (drug-event, stage, dynamic) triples with up to a given amount of drug event reports.

209

15

Table 1 Real-world pediatric drug-event detection performance. The area under the receiver operating characteristic curve (AUROC) and sensitivity or true positive rate to detect real-world pediatric drug-events observed within FAERS per each method and score type. The prediction threshold for the sensitivity was the null statistic for each method (null threshold: GAM==0; PRR==1). The performance interval is the 95% confidence interval.

	Real-world pediatric drug-event detection performance							
		AUI	ROC			Sensi	tivity	
	90mse		score		90mse		score	
	PRR	GAM	PRR	GAM	PRR	GAM	PRR	GAM
Performance value	0.62 [0.58, 0.66]	0.65 [0.59, 0.69]	0.62 [0.58, 0.67]	0.73 [0.69, 0.77]	0.28 [0.22, 0.36]	0.28 [0.23, 0.35]	0.49 [0.40, 0.56]	0.85 [0.81, 0.89]

210



Fig. 6 GAM and PRR performance to detect dynamic patterns of rare adverse events. The AUROC for detecting various classes of drug event reporting dynamics as event reporting was reduced at child development stages. The event reporting for drug-event pairs was reduced at 10% decrements only within a specific child development stage. For example, 0% event reporting reduction indicates no reduction in event reporting and 100% event reporting reduction indicates all event reports were removed.

16

Table 2 ADE detection method risk score quality and significance on real-world pediatric drug-events. The number of drug-event pairs that contained a child development stage with a risk score of each score quality (null threshold: GAM==0; PRR==1). A 90% lower bound score above the null threshold indicates a significant risk.

Number of drug- event pairs with score quality in atleast one stage	Zero	NaN	Finite	Infinite	Score above null	90% lower bound above null
GAM	0	0	26	0	26	14
PRR	23	14	25	5	26	18

17



Fig. 7 GAM and PRR detection scores on putative real-world dynamic adverse drug events. We highlight two psychiatric adverse events, A) Paranoia and B) Affective Disorder, from exposure to the drug montelukast exhibiting dynamic ADE risks across child development stages.

213

214 Methods

- 215 *ADE data source*
- 216 We retrieved drug event reports from the Food and Drug Administration's openFDA⁴⁶ download
- 217 page, utilizing an API key with extended permissions, containing the FAERS data. Using custom

18

218 python notebooks and scripts available in the 'openFDA drug event-parsing' github repository 219 (DOI: 10.5281/zenodo.4464544), we extracted and formatted all drug event reports prior to the 220 third quarter of 2019. Data fields included the safety report identifier, age value, age code 221 e.g. year, adverse event MedDRA concept code (preferred terms), and drug RxNorm code 222 (various) used in our analyses. The age value was standardized to year units for categorizing 223 reports into the 7 child development stages according to the Eunice Kennedy Shriver National 224 Institute of Child and Human Development⁴⁵. Adverse drug event MedDRA codes were mapped to standard concept identifiers using concept tables⁴⁸ from the OMOP common data model. The 225 226 drug RxNorm code was similarly translated to the standard RxNorm concept identifier 227 (ingredient level) in OMOP and was further mapped to the equivalent ATC concept identifier 228 (ATC 5th level) using the concept relationship table. The occurrence of an adverse drug event is 229 defined as any safety report where both the adverse event and drug concepts are reported 230 together. The pediatric report space for any adverse drug event is all reports which have age 231 above zero and less than or equal to 21 years old which is the upper bound for the late 232 adolescence child development stage. The drug event data for a given drug-event pair composed 233 of 339,741 safety reports with a binary indicator for reports of the event and drug, as well as the 234 category of NICHD child development stage for the report's patient.

235 Simulated ADE dynamics

236 The objective of this study was to evaluate detection of drug-event reporting as the reporting rate

237 changes across child development stages with varying dynamics and effect sizes. We assert that

238 reporting dynamics during childhood reflect ontogenic profiles observed on molecular,

functional, and structural levels^{7,37,38}.

240	We simulated dynamic ADE reporting by combining hyperbolic tangent functions that produced
241	symmetric probability distributions around a given effect size to define the probability of event
242	reporting at drug reports. These dynamic reporting classes represent nonlinear trends of drug-
243	event reports across childhood. The average drug and event reporting across reports equaled the
244	event reporting rate multiplied by a fold change factor resulting in the effect size of dynamic
245	drug event reporting. The fold change followed a negative exponential distribution with rate
246	parameter 0.75 resulting in a fold change distribution ranging from 1 to 10 (Figure S9). The
247	simulated reporting probabilities were distributed to safety reports in age ascending order
248	reflecting a desired dynamic distribution of ADE reporting across childhood. We designed 5
249	different dynamic reporting rates, namely 'uniform' (random), 'increase', 'decrease', 'plateau',
250	and 'inverse_plateau' (Figure S10).
251	ADE data augmentation
252	We augmented the original drug event data from FAERS with the simulated drug event reporting
253	dynamics. We randomly selected 500 drug-event pairs to be the positive control set. We
254	augmented the drug event data for each pair with dynamics previously described that we want to
255	detect. We then randomly selected 10,000 mutually exclusive drug-event pairs to be the negative
256	control set which were not augmented and represented reporting of drugs with events within
257	FAERS. Differences of the average drug event reporting between the drug-event sets was
258	computed by comparing 10 million resamples of each distribution.
259	
260	Augmenting the positive control drug-event pairs resulted in 5 sets of 500 drug-event pairs,
261	forming (drug-event stage dynamic) triples. The (drug-event stage uniform dynamic) triple

20

262	scores were the reference distribution for comparing the average difference in scores, after 20
263	resamples, with ADE risk scores from the other dynamics classes.

264 ADE detection methods

265 We applied two ADE detection methods to the positive and negative control drug-event sets. We

chose a population stratification (PRR) and modeling (GAM) method to evaluate detection of

ADE dynamics when stratifying the data or by sharing information across child development

stages, respectively.

269 We employed the Proportional Reporting Ratio (PRR):

$$\frac{\frac{a}{a+c}}{\frac{b}{b+d}}$$

where 'a' is the number of reports with the drug and event, 'b' is the number of reports without the drug and with the event, 'c' is the number of reports with the drug and without the event, and 'd' is the number of reports without the drug or event of interest. The resulting score is the event reporting prevalence with the drug compared to without the drug. We generated PRR scores for each child development stage resulting in 7 scores for each drug-event pair. The PRR scores were log10 transformed when conducting the Shapiro-Wilk test for normality.

277 We also evaluated the logistic generalized additive model⁴⁹ (GAMs):

278
$$g(E(Event)) = s(nichd) * Drug$$

where g is a logit link function, E(Event) is the expected value of event reporting, s is a spline function with a penalized cubic basis, *nichd* is the child development stage of the report's

21

subject, and *Drug* is an indicator i.e. 0 or 1 of drug reporting. Details for GAMs can be found at references^{42,50} and we specified the model using the *mgcv* package in R.

283 Briefly, the GAM is a flexible statistical model that captures nonlinear effects of covariates onto 284 a response. In this paper, we model the effect of the child development stage interacting with 285 drug reporting on the reporting of an event where the event is the reporting of the MedDRA preferred term and the drug is the reporting of the ATC 5th level drug concept. The s() function 286 287 is a spline function where the interaction of the child development stage (main effect) and the 288 drug (interaction using the 'by' variable) is modeled according to a set of basis functions. Each 289 development stage defines the knot (7 in total) in which the expectation of event reporting is 290 quantified. In the spline function, a penalized cubic spline basis (bs='cs') is used for fitting the 291 basis functions where the first and second derivative of the event expectation is zero at each 292 knot, resulting in a smooth event expectation across stages. To mitigate overfitting or 293 'wiggliness', we used a penalized iterative restricted likelihood approach, called 'fREML', with 294 a wiggliness penalty in the objective function. Fitting the GAM model (using the 'bam' function 295 and discrete=T) produces coefficient terms, similar to beta coefficients in logistic regression, for 296 each child development stage for the association of the adverse event being reported in 297 interaction with reporting the drug. We generated GAM scores for each child development stage 298 resulting in 7 scores for each drug-event pair. It is important to note that all GAM scores 299 produced were finite, nonzero values.

The scores generated by each method have different variations and uncertainty in the estimatedpopulation value. We additionally determined the lower confidence bound in which the

302 population-based score would be greater than 90% of score replicates. The population score and

22

the 90% lower confidence bound, called 'score' and '90mse' respectively, are the score types foreach method.

305 *ADE dynamic detection power analysis*

306 We performed a power analysis to determine which of the positive control drug-event pairs could 307 be detected for each method and score type. The generated scores may not show a drug and event 308 association (score above the null statistic or a significance association) for a child development 309 stage due to the method's different assumptions and biases when applied onto observational data. 310 To mitigate these issues, we determined the drug event data characteristics, namely the number 311 of drug reports and the effect size, for each method in which reporting dynamics could be 312 detected at or above t = 80% power or true positive rate. Specifically, for the (drug-event, stage, 313 dynamic) triple scores in the positive control set, we determined the power to differentiate scores 314 at high reporting rates about a given score threshold (GAM score threshold==0; PRR score 315 threshold==1). The reporting rates were higher at different child development stages for each 316 dynamics class e.g. the 'increase' dynamics class had higher reporting at the 'early' adolescence' 317 and 'late adolescence' stages (Table S1). The scores from (drug-event, stage, dynamic) triples 318 with a high reporting rate were only considered for reflecting dynamic drug event reporting 319 associations. The scores from (drug-event, stage, dynamic) triples with a low reporting rate were 320 not considered further due to spurious scores generated at stages without injected signal. The 321 drug event characteristics were determined for both the estimated population score ('score') and 322 the 90% lower bound score ('90mse') that represent scores with lower and higher confidence, 323 respectively, for the 'true' population score.

23

324 Choosing drug-event pairs at or exceeding the characteristics for each method and score type at 325 or above t = 80% power resulted in a superset of (drug-event, stage, dynamic) triples designated 326 as positives in a reference standard for each drug event reporting dynamics class (Table S2). The 327 negative control set contained the same (drug-event, stage) doubles or 70,000 scores for each 328 reference standard. Excluding the drug-event scores generated by the uniform class, there were 4 329 reference standards of positive and negative drug-event pairs for each ADE reporting dynamics 330 class used for detection performance evaluation.

ADE dynamic detection performance

332 We evaluated the GAM and PRR methods to detect drug event reporting dynamics across the 333 child development stages. Specifically, we determined the performance in differentiating scores 334 from (drug-event, stage, dynamic) triples in the positive control set versus the negative control 335 (drug-event, stage) score doubles. The positive control set contained a superset of the 500 (drug-336 event, stage, dynamic) score triples (Table S2). The negative control set contained the same 337 (drug-event, stage) doubles or 70,000 scores for each reference standard. For each of the four 338 reference standards, we quantified performance metrics including the sensitivity, specificity, and 339 area under the receiver operating characteristic (AUROC) curve using the R package ROCR for 340 each detection method and score type. Confidence intervals for the AUROC were calculated 341 through bootstrapping (100 resamples) the score distributions and calculating performance 342 metric values.

343 *Dynamics sensitivity analysis*

We assessed the sensitivity of the ADE detection methods to detect drug event reporting
dynamics within child development stages. We artificially reduced, at 10% decrements, the event

24

346	reporting rate at each child development stage separately. Specifically, at each reduced stage, we
347	determined the sensitivity of each method and score type to detect (drug-event, stage, dynamic)
348	score triples compared to the same negative control (drug-event, stage) score doubles at that
349	same reduced stage. Sensitivity was assessed iteratively at the 10% decrements within each child
350	development stage. We calculated the AUROC and power metrics to quantify sensitivity to drug
351	event reporting dynamics for each method and score type.

352 Real-world ADE validation

353 We applied the ADE detection methods on observed FAERS data for drug-event pairs within the

pediatric drug-event reference standard from the Global Research in Pediatrics consortium⁵¹. A

355 machine-readable dataset can be found at the 'GRiP_pediatric_ADE-reference_set' github

repository (DOI: 10.5281/zenodo.4453379). We assigned drug-event pairs with epidemiological

357 or mechanistic evidence in children (Control=='C') as the positive class (N=26), and the cross-

358 product of all drugs and events that were complementary to drug-event pairs in the reference set

as the negative class (N=123). We calculated the AUROC using the *ROCR* package in R and the

true positive rate using the null statistic of each method as the prediction threshold.

361 List of Abbreviations

362 ADE: adverse drug event; FAERS: Food and Drug Administration Adverse Event Reporting

363 System; GAM: generalized additive model; PRR: proportional reporting ratio; NICHD: national

364 institute of child and human development; AUROC: area under the receiver operating

365 characteristic curve; TPR: true positive rate; ATC: anatomical therapeutic class; DOI: digital

366 object identifier.

25

367 Availability of Data and Materials

- 368 The datasets and code supporting the conclusions of this article are available in the
- 369 'evaluating_ontogenic_ade_risk' Github repository, DOI: 10.5281/zenodo.4585585.

370

- 371 **Declarations**
- 372 None.

373 **References**

374	1.	Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of
375		adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis
376		of prospective studies. Br J Clin Pharmacol. 2001;52(1):77-83. doi:10.1046/j.0306-
377		5251.2001.01407.x
378	2.	Smyth RMD, Gargon E, Kirkham J, et al. Adverse drug reactions in childrena systematic
379		review. PLoS One. 2012;7(3):e24061. doi:10.1371/journal.pone.0024061
380	3.	Giangreco NP, Elias JE, Tatonetti NP. No population left behind: Improving paediatric
381		drug safety using informatics and systems biology. Br J Clin Pharmacol. Published online
382		December 17, 2020:bcp.14705. doi:10.1111/bcp.14705
383	4.	Benjamin DK, Smith PB, Sun MJM, et al. Safety and Transparency of Pediatric Drug
384		Trials. Arch Pediatr Adolesc Med. 2009;163(12):1080-1086.
385		doi:10.1001/archpediatrics.2009.229

- 386 5. de Bie S, Ferrajolo C, Straus SMJM, et al. Pediatric Drug Safety Surveillance in FDA-
- 387 AERS: A Description of Adverse Events from GRiP Project. Garattini S, ed. *PLoS One*.
- 388 2015;10(6):e0130399. doi:10.1371/journal.pone.0130399
- 389 6. Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety: need for more efficient
- 390 clinical translation of pharmacovigilance knowledge. *J Popul Ther Clin Pharmacol = J la*
- *Ther des Popul la Pharmacol Clin.* 2011;18(2):e76-88.
- 392 http://journals.sagepub.com/doi/10.1038/jcbfm.2012.176
- 393 7. Crespi B. The evolutionary biology of child health. *Proc R Soc B Biol Sci.*
- 394 2011;278(1711):1441-1449. doi:10.1098/rspb.2010.2627
- Yaffe S, Estabrook RW, Pitluck S, Davis JR. *Rational Therapeutics for Infants and Children.*; 2000. doi:10.17226/9816
- 397 9. Johnson T. The development of drug metabolising enzymes and their influence on the
- 398 susceptibility to adverse drug reactions in children. *Toxicology*. 2003;192(1):37-48.
- 399 doi:10.1016/S0300-483X(03)00249-X
- 400 10. Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug
 401 reactions in children. *Pharmacogenomics*. 2010;11(11):1591-1602.
- 402 doi:10.2217/pgs.10.146
- 403 11. de Graaf-Peters VB, Hadders-Algra M. Ontogeny of the human central nervous system:
- 404 What is happening when? *Early Hum Dev.* 2006;82(4):257-266.
- 405 doi:10.1016/j.earlhumdev.2005.10.013
- 406 12. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans

407	from infancy to old age.	Proceedings Biol Sci.	. 2015;282(1821):20143085.
-----	--------------------------	-----------------------	----------------------------

- 408 doi:10.1098/rspb.2014.3085
- 409 13. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-
- 410 Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy.
- 411 *Med Res Rev.* 2014;34(1):106-135. doi:10.1002/med.21280
- 412 14. Guo H-L, Jing X, Sun J-Y, et al. Valproic Acid and the Liver Injury in Patients with
- 413 Epilepsy: An Update. *Curr Pharm Des.* 2019;25(3):343-351.
- 414 doi:10.2174/1381612825666190329145428
- 415 15. Moon YE. Paradoxical reaction to midazolam in children. *Korean J Anesthesiol*.
- 416 2013;65(1):2-3. doi:10.4097/kjae.2013.65.1.2
- 417 16. Kawakami Y, Fujii S, Ishikawa G, Sekiguchi A, Nakai A, Takase M. Valproate-induced
- 418 polycystic ovary syndrome in a girl with epilepsy: A case study. *J Nippon Med Sch*.
- 419 2018;85(5):287-290. doi:10.1272/jnms.JNMS.2018_85-46
- 420 17. Cui N, Wu F, Lu W, et al. Doxorubicin-induced cardiotoxicity is maturation dependent
 421 due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
- 422 *N*. 2019;23(7):4627-4639. doi:10.1111/jcmm.14346
- 423 18. Park SO, Wamsley HL, Bae K, et al. Conditional Deletion of Jak2 Reveals an Essential
- Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in
 Humans. *PLoS One*. 2013;8(3):1-14. doi:10.1371/journal.pone.0059675
- 426 19. Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effect of ibotenate on brain
- 427 development: An excitotoxic mouse model of microgyria and posthypoxic-like lesions. J

428		Neuropathol Exp Neurol. 1995;54(3):358-370. doi:10.1097/00005072-199505000-00009
429	20.	Jiang X-L, Zhao P, Barrett J, Lesko L, Schmidt S. Application of Physiologically Based
430		Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics
431		in Children. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):80.
432		doi:10.1038/psp.2013.55
433	21.	Krekels EHJ, Neely M, Panoilia E, et al. From pediatric covariate model to
434		semiphysiological function for maturation: Part I-extrapolation of a covariate model from
435		morphine to zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012;1(1):1-8.
436		doi:10.1038/psp.2012.11
437	22.	Baldrick P. Juvenile animal testing in drug development - Is it useful? Regul Toxicol
438		Pharmacol. 2010;57(2-3):291-299. doi:10.1016/j.yrtph.2010.03.009
439	23.	Goulooze SC, Zwep LB, Vogt JE, et al. Beyond the Randomized Clinical Trial:
440		Innovative Data Science to Close the Pediatric Evidence Gap. Clin Pharmacol Ther.
441		2020;107(4):786-795. doi:10.1002/cpt.1744
442	24.	Brussee JM, Calvier EAM, Krekels EHJ, et al. Children in clinical trials: towards
443		evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic
444		modeling. Expert Rev Clin Pharmacol. 2016;9(9):1235-1244.
445		doi:10.1080/17512433.2016.1198256
446	25.	Christensen ML, Davis RL. Identifying the "Blip on the Radar Screen": Leveraging Big
447		Data in Defining Drug Safety and Efficacy in Pediatric Practice. J Clin Pharmacol.
448		2018;58(January):S86-S93. doi:10.1002/jcph.1141

- 449 26. Tatonetti NP. Translational medicine in the Age of Big Data. Brief Bioinform.
- 450 2019;20(2):457-462. doi:10.1093/bib/bbx116
- 451 27. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development:
- 452 Recommendations and obligations beyond phase 3. *Am J Public Health*. 2008;98(8):1366-
- 453 1371. doi:10.2105/AJPH.2007.124537
- 454 28. Etwel FA, Rieder MJ, Bend JR, Koren G. A Surveillance Method for the Early
- 455 Identification of Idiosyncratic Adverse Drug Reactions. *Drug Saf.* 2008;31(2):169-180.
- 456 doi:10.2165/00002018-200831020-00006
- 457 29. Star K, Sandberg L, Bergvall T, Choonara I, Caduff-Janosa P, Edwards IR. Paediatric
- 458 safety signals identified in VigiBase: Methods and results from Uppsala Monitoring
- 459 Centre. *Pharmacoepidemiol Drug Saf.* 2019;28(5):680-689. doi:10.1002/pds.4734
- 460 30. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal
- generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf.*2001;10(6):483-486. doi:10.1002/pds.677
- 463 31. Osokogu OU, Dodd C, Pacurariu A, Kaguelidou F, Weibel D, Sturkenboom MCJM. Drug
- 464 Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact
- 465 of Age Stratification. *Drug Saf.* 2016;39(9):873-881. doi:10.1007/s40264-016-0433-x
- 466 32. Hastie T, Tibshirani R, Friedman J. *Elements of Statistical Learning*. 2nd editio. Springer;
 467 2008. http://web.stanford.edu/~hastie/pub.htm
- Guisan A, Edwards TC, Hastie T. Generalized linear and generalized additive models in
 studies of species distributions: setting the scene. *Ecol Modell*. 2002;157(2-3):89-100.

30

470 doi:10.1016/S0304-3800(02)00204-1

471	34.	Yin Q, Wang J. The association between consecutive days' heat wave and cardiovascular
472		disease mortality in Beijing, China. BMC Public Health. 2017;17(1):1-10.

- 473 doi:10.1186/s12889-017-4129-7
- Tamayo-Uria I, Mateu J, Escobar F, Mughini-Gras L. Risk factors and spatial distribution
 of urban rat infestations. *J Pest Sci (2004)*. 2014;87(1):107-115. doi:10.1007/s10340-0130530-x
- 477 36. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and
- toddlers: pediatric pharmacovigilance between present and future. *Expert Opin Drug Saf.*

479 2012;11(1):95-105. doi:10.1517/14740338.2011.584531

- 480 37. Saghir SA, Khan SA, McCoy AT. Ontogeny of mammalian metabolizing enzymes in
- 481 humans and animals used in toxicological studies. *Crit Rev Toxicol*. 2012;42(5):323-357.
- 482 doi:10.3109/10408444.2012.674100
- 483 38. Gunewardena SS, Yoo B, Peng L, et al. Deciphering the Developmental Dynamics of the
- 484 Mouse Liver Transcriptome. Buratti E, ed. *PLoS One*. 2015;10(10):e0141220.
- 485 doi:10.1371/journal.pone.0141220
- 486 39. Bohn J, Kortepeter C, Muñoz M, Simms K, Montenegro S, Dal Pan G. Patterns in
- 487 spontaneous adverse event reporting among branded and generic antiepileptic drugs. *Clin*
- 488 *Pharmacol Ther*. 2015;97(5):508-517. doi:10.1002/cpt.81
- 489 40. Bagattini F, Karlsson I, Rebane J, Papapetrou P. A classification framework for exploiting
 490 sparse multi-variate temporal features with application to adverse drug event detection in

41.

0717-4

medical records. BMC Med Inform Decis Mak. 2019;19(1):1-21. doi:10.1186/s12911-018-

Zhao J, Papapetrou P, Asker L, Boström H. Learning from heterogeneous temporal data in

494		electronic health records. J Biomed Inform. 2017;65:105-119.
495		doi:10.1016/j.jbi.2016.11.006
496	42.	Wood SN. Generalized Additive Models: An Introduction with R, Second Edition.; 2017.
497		doi:10.1201/9781315370279
498	43.	Helwig NE. Regression with ordered predictors via ordinal smoothing splines. Front Appl
499		Math Stat. 2017;3(July):1-13. doi:10.3389/fams.2017.00015
500	44.	Simpson D, Rue H, Riebler A, Martins TG, Sørbye SH. Penalising model component
501		complexity: A principled, practical approach to constructing priors. Stat Sci. 2017;32(1):1-
502		28. doi:10.1214/16-STS576
503	45.	Williams K, Thomson D, Seto I, et al. Standard 6: Age groups for pediatric trials.
504		Pediatrics. 2012;129(SUPPL. 3):S153-S160. doi:10.1542/peds.2012-00551
505	46.	Kass-Hout TA, Xu Z, Mohebbi M, et al. OpenFDA: An innovative platform providing
506		access to a wealth of FDA's publicly available data. J Am Med Informatics Assoc.
507		2016;23(3):596-600. doi:10.1093/jamia/ocv153
508	47.	Giangreco NP. ngiangre/openFDA_drug_event_parsing: Repository for python notebooks
509		and scripts for parsing the json-formatted drug event reports collected by the FDA.
510		Published online 2021. doi:https://zenodo.org/badge/latestdoi/246321623
511	48.	OHDSI. Athena. Accessed January 17, 2021. https://athena.ohdsi.org/search-terms/start

512	49.	Buja BYA, Hastie T, Tibshirani R. Linear Smoothers and Additive Models.
-----	-----	---

- 513 2016;17(2):453-510.
- 514 https://scholar.google.com/scholar_lookup?journal=The+Annals+of+Statistics&title=Line
- ar+smoothers+and+additive+models&author=A+Buja&author=T+Hastie&author=R+Tibs
- 516 hirani&publication_year=1989&pages=453-510&
- 517 50. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods
- 518 *Med Res.* 1995;4(3):187-196. doi:10.1177/096228029500400302
- 519 51. Osokogu OU, Fregonese F, Ferrajolo C, et al. Pediatric drug safety signal detection: a new
- 520 drug-event reference set for performance testing of data-mining methods and systems.
- 521 Drug Saf. 2015;38(2):207-217. doi:10.1007/s40264-015-0265-0
- 522 52. Giangreco N. GRiP_pediatric_ADE-reference_set. Published 2020. Accessed October 21,

523 2020. https://github.com/ngiangre/GRiP_pediatric_ADE-reference_set

- 524 53. Giangreco NP. ngiangre/evaluating_ontogenic_ade_risk. Published online 2021.
- 525 doi:10.5281/zenodo.4585585



Fig. S1 Drug event reporting for positive and negative controls. The distribution of drug-event reporting between positive and negative control set drug-event pairs across A) dynamics classes and B) child development stages.



Fig. S2 Power graph detecting drug-event pairs with dynamics for each method and score type. The number of drug reports and effect size determined the scores evaluated to detect an association between the drug and event co-occurrence. The scores used were from child development stages with a high reporting rate determined by the dynamic class.



Fig. S3 GAM and PRR detection sensitivity at low drug event reporting. The sensitivity or true positive rate was computed for each method and score type to detect dynamics only utilizing (drug-event, stage, dynamic) triples with a given amount of drug event reports.

528



Fig. S4 Drug and event reporting as adverse events become rare at child development stages. The average number of drug, event, and drug event reports are shown at each child development stage as event reporting is reduced by 10% at each child development stage.

37



Fig. S5 GAM and PRR detection scores across childhood as adverse events become rare. The average ADE risk scores are shown at each child development stage as event reporting is reduced by 10% at each child development stage.

531

530



Fig. S6 GAM and PRR score comparison for real-world pediatric drug-events. Application of each ADE detection method on drug-event pairs from the clinically-validated GRiP pediatric reference set. The population score and 90% confidence interval are shown for each detection method. Only drug-event pairs with epidemiological or mechanistic evidence in children are shown.

39



Fig. S7 GAM and PRR drug event real-world drug-event detection performance. A) The area under the receiver operating characteristic curve (AUROC) for detecting risk in real-world pediatric drug-event pairs. B) The true positive rate (TPR) for detecting risk in real-world pediatric drug-event pairs. Intervals represent the 95% confidence interval for the performance metric.



Fig. S8 GAM and PRR detection scores on sample real-world and simulated drug event data. We highlight two drug-event pairs from the A) real-world and B) simulated positive control set where scores across child development stages reflect dynamic ADE risks.



Fig. S9 Distribution of fold-changes for generating drug event dynamics of varying magnitudes. Distribution of fold-changes randomly assigned to drug-event pairs in the positive control set for each dynamics class.



— decrease — increase — inverse_plateau — plateau — uniform

Fig. S10 Drug event reporting probability rates across child development stages. Each dynamics class represents a drug event reporting probability trend for drug-event pairs in the positive control set. An effect size, here 0.3, determined the magnitude of the drug event reporting dynamic. The average drug and event reporting across reports equaled the event reporting rate multiplied by a fold change factor resulting in the effect size of dynamic ADE reporting.

Table S1 High and low drug, event reporting at child development stages for across each dynamics class.

Relative reporting rate within drug-event pairs at child development stages		NICHD child development stages							
		Term neonatal	Infancy	Toddler	Early childhood	Middle childhood	Early adolescence	Late adolescence	
Drug event dynamics	Decrease	High	High	NA	NA	NA	Low	Low	
classes	Increase	Low	Low	NA	NA	NA	High	High	
	Inverse Plateau	High	NA	Low	Low	Low	NA	High	
	Plateau	Low	NA	High	High	High	NA	Low	
	Uniform	NA	NA	NA	NA	NA	NA	NA	

Table S2 The number of drug-event pairs after the dynamics power analysis. Methods and scores had differences in drug reporting and effect size thresholds to identify drug, event pairs with atleast 80% power to differentiate scores between high and low reporting development stages.

Number of dr	ug-event nairs	Drug event dynamics class						
after the po	wer analysis	Decrease Increase		Inverse Plateau	Plateau			
	PRR	282 (56.4%)	283 (56.6%)	282 (56.4%)	282 (56.4%)			
Secre	PRR_90mse	109 (21.8%)	109 (21.8%)	109 (21.8%)	109 (21.8%)			
Score	GAM	109 (21.8%)	109 (21.8%)	109 (21.8%)	109 (21.8%)			
	GAM_90mse	68 (13.6%)	68 (13.6%)	68 (13.6%)	68 (13.6%)			